The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy.
A. Bessudo
No relevant relationships to disclose
J. C. Bendell
No relevant relationships to disclose
N. Gabrail
No relevant relationships to disclose
M. V. Kopp
No relevant relationships to disclose
L. Mueller
No relevant relationships to disclose
L. L. Hart
No relevant relationships to disclose
V. I. Vladimirov
No relevant relationships to disclose
A. U. Pande
Employment or Leadership Position - Daiichi Sankyo
I. Gorbatchevsky
Employment or Leadership Position - Daiichi Sankyo
C. Eng
No relevant relationships to disclose